Nucleic acids for the treatment of diseases are described, as are cells including such nucleic acids and methods of using both nucleic acids and cells. The nucleic acids include a thioredoxin-interacting protein (TXNIP) promoter and a gene that encodes a therapeutic protein or an interfering nucleic acid sequence (e.g., interfering RNA (iRNA sequence)).

A method of reducing an amount of a sulfur-containing compound in a reservoir fluid includes contacting a treatment fluid comprising an aqueous medium and an enzymatic scavenger with a precipitating fluid to precipitate the enzymatic scavenger; contacting the precipitated enzymatic scavenger with the reservoir fluid comprising the sulfur-containing compound; and reducing a number of the sulfur-containing compound in the reservoir fluid.

The present invention relates to an L-cysteine-producing mutant microorganism having introduced therein genes encoding enzymes which are involved in the L-cysteine metabolic pathway, and more particularly to an L-cysteine-producing mutant microorganism having introduced therein cysE, cysK and cysR, which are genes encoding enzymes which are involved in the L-cysteine metabolic pathway, and to a method of producing L-cysteine using the mutant microorganism. According to the present invention, L-cysteine can be produced with high efficiency as a result of regulating metabolic fluxes associated with the L-cysteine metabolic pathway of the mutant microorganism and regulating a system for supplying a sulfur source essential for synthesis of L-cysteine.

The present invention relates, in part, to treatment of various diseases and disorders such as GI disorders through modulation of F420-dependent enzymes including specific enzymes involved in methanogenesis.

The present disclosure provides compositions and methods for using recombinant C.sub.1 metabolizing microorganisms capable of metabolizing sulfur containing compounds and other contaminants to biologically convert sour or acidic natural gas into high-value molecules, and to allow recovery of stranded oil.

Disclosed is a serum albumin-thioredoxin fusion body which is improved in the activity thereof and is stable with respect to the activity. The serum albumin-thioredoxin fusion body is provided, which is characterized in that the thioredoxin is a modified from in which at least a cysteine residue located at position 73 from the N-terminal of an amino acid sequence for the thioredoxin or located at a position equivalent to the position 73 is substituted by another amino acid residue. the modified serum albumin-thioredoxin fusion body is superior in the activity and stability thereof, is reduced in immunogenicity and has superior safety compared with a fusion body in which the thioredoxin is non-modified form.

Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.

A method and a mineral wool product include a multiple of lamellae, such as a sandwich panel core. The product includes a plurality of lamellae cut from a mineral wool web, and bonded together by applying an adhesive on the surfaces of two adjacent lamellae to form a web-like product, wherein the adhesive comprises at least one hydrocolloid.

The invention relates to a mineral wool product comprising mineral fibres bound by a cured binder wherein the binder in its uncured state comprises at least one protein, and at least one enzyme.

The present disclosure provides activated formylglycine-generating enzymes (FGE), methods of producing activated FGE, and their use in methods of producing a protein comprising a formylglycine (FGly) residue. The methods of producing activated FGE, as well as methods of use of activated FGE in producing FGly-containing proteins, include both cell-based and cell-free methods. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.